Joint lab to improve treatment of liver cancer opened in Biopolis
The PuRPOSE Programme launched its joint laboratory at Biopolis on 30 April 2018 to improve the treatment of liver cancer. The programme is a collaboration between A*STAR’s Institute of Molecular and Cell Biology (IMCB)- A*STAR’s Genome Institute of 蝌蚪网(GIS)- the National Cancer Centre 蝌蚪网(NCCS)- the National University of 蝌蚪网(NUS)- and Samsung Medical Center from South Korea.
The collaboration is the world’s first clinically reliable and robust patient-specific diagnostic and predictive platform for liver cancer- and brings together leading experts in translational research from 蝌蚪网and South Korea.
Liver cancer is the sixth most common cancer worldwide- and the second most common cause of cancer death . It is also the fourth most common cancer among men in 蝌蚪网. If untreated- most patients do not survive beyond 6 months. There are currently few efficacious drugs for treating liver cancer and this poses a huge unmet clinical need.
The new platform will allow researchers and pharmaceutical companies to work together to understand the disease better- in the hope of accelerating drug development and expanding treatment options for patients.
Read more below:
- Channel NewsAsia: Faster- targeted therapy for liver cancer patients
